glp-1 asa guidelines The 2023 position on receptor agonists has been overturned by three 2025 consensus statements. Continue the drug. Change the fast. ANZCA/ADS/GESA/NACOS, the Association of Anaesthetists/RCoA, and SPAQI/AACE now converge on GLP-1 RA guidance roundup -

Result: high adherence, slower initiation, lower commercial upside for premium brands

doi: 10.1016/j.mtbio.2023.100782 [DOI] [PMC free article] [PubMed] [Google Scholar] 66.Liu X, Li Y, Wang S, et al

Homeostatic model assessment (HOMA) 2-B provides a validated tool to assess beta-cell function

How they enter the body is different, and that affects effectiveness and convenience

Emerging research and clinical trial data suggest a link between semaglutide weight loss drugs and delayed gastric emptying, which may contribute to these digestive issues

And it acts on brain regions involved in satiety, particularly the hypothalamus and brainstem